-
1by Nathalie Vernaz, Guy Haller, François Girardin, Benedikt Huttner, Christophe Combescure, Pierre Dayer, Daniel Muscionico, Jean-Luc Salomon, Pascal Bonnabry“... medication after patent termination. These include marketing of slightly modified follow-on drugs. We aimed...”
Published 2013-01-01
Get full text
Article -
2